Sublingual DMT + harmine creates a controllable, repeatable psychedelic session — but 'controllable' must be proven in trial data, not just claimed in slides. Videra Health captures the dose-response, session-to-session consistency, and integration patterns that turn 'novel formulation' into 'differentiated asset.'
See how we'd observe REDIReconnect Labs' sublingual DMT plus harmine program — an ayahuasca-derived formulation engineered for controllable session duration, repeatable dosing, and clinic-administered care.
REDI is sublingual DMT + harmine — an ayahuasca-derived formulation engineered for controllable session duration, repeatable dosing, and clinic-administered care. The hypothesis: capture the durable therapeutic effects associated with ayahuasca, in a format that fits modern clinical infrastructure.
Sublingual administration means clinicians can dose, monitor, and adjust without the complexity of traditional ayahuasca preparation. The session is more controllable, the experience more reproducible. In theory.
'Controllable' has to be proven, not assumed. Observable behavioral measurement during and across sessions captures the dose-response, session-to-session consistency, and integration patterns that turn 'novel formulation' into 'differentiated asset.' Standard endpoints capture symptoms. They don't capture session dynamics.
The market opportunity is built on the assumption that ayahuasca-like benefits can be productized. Proving it requires data the standard endpoint stack was not built to capture.
Building the case for productized ayahuasca-derived therapy.
Four observation gaps separate 'sublingual DMT + harmine' from 'differentiated psychedelic asset.'
Session-to-session variability in onset, peak, and integration phases is observable in vocal, facial, and somatic signal. The data that turns 'controllable' from a marketing word into a clinical finding.
Behavioral observation across dose levels surfaces the dose-response curve in a way that supports both label claims and clinical dosing guidance.
Post-session integration is where the therapeutic durability is forged. Continuous behavioral capture between sessions surfaces the integration patterns that predict outcomes.
Whether REDI delivers the durable benefits associated with ayahuasca depends on what trial data shows about session dynamics, integration, and longitudinal outcomes. Videra captures all three.
Our platform pairs in-clinic AI hardware with multimodal behavioral analytics and a custom algorithm engine, already proven in TDScreen and Check on Mom. Here's how each maps to REDI.
A clinical-grade camera and directional audio rig that drops into any REDI Phase 1 site in minutes. Every session captured at the same fidelity — the baseline for proving session-to-session consistency and dose-response.
Multimodal analysis of voice, video, and language during the sublingual session and across the integration period that follows. The data that supports the 'productized ayahuasca' commercial story.
For REDI, that means a proprietary controllability index and integration pattern model — measuring what 'controllable session' actually looks like in trial data, and predicting durability from session-level signal.
AI-powered tardive dyskinesia screening built on the AIMS standard. AUC 0.89 vs. trained raters, peer-reviewed in J Clin Psychiatry.
Conversational AI + video screener for postpartum depression. Used in real homes, on real devices, validated against clinical frameworks.
Multimodal AI model trained on REDI Phase 1+ data, quantifying session controllability, integration depth, and durability prediction for the ayahuasca-derived commercial story.
Your REDI development strategy, mapped to Videra capabilities in production.
Videra's network isn't our customer base. It's the living dataset that powers every algorithm we build. For Reconnect Labs, that means real clinical depth and peer-reviewed validation.
We'd welcome a 30-minute session to walk Reconnect Labs through a tailored, protocol-by-protocol proposal for REDI's clinical development plan.